

Selected Clinical Research Protocols for Pancreatic Cancer

Diagnostic/Genetic

NCI-03-C-0145 Diagnostic and Genetic Study in Patients With Von Hippel-Lindau Syndrome and Pancreatic Lesions

Chairperson: Steven Libutti, MD. Telephone: 301-496-5049. Lead organization: Center for Cancer Research. Age range: 12 and over.

Phase III

CPMC-IRB-8544; NCCAM; NCI-V99-1538 Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

Chairperson: John Chabot, MD. Telephone: 212-305-9468. Lead organization: Herbert Irving Comprehensive Cancer Center. Age range: 18 to 65.

EORTC-40013, EORTC-22012, FFCD-EORTC-40013 Phase II/III Randomized Study of Gemcitabine and Radiotherapy Versus Observation After Prior Curative Resection in Patients With Pancreatic Head Adenocarcinoma

Chairperson: Jean-Luc Van Laethem, MD. Telephone: 32-2-555-3712. Lead organization: EORTC Gastrointestinal Tract Cancer Group. Age range: 18 and over.

NCRI-ESPAC-3, CAN-NCIC-PA2, EU-20043 Phase III Randomized Adjuvant Study of Gemcitabine Versus Fluorouracil and Leucovorin Calcium Versus Observation in Patients With Completely Resected Pancreatic Cancer

Chairperson: John Neoptolemos, MD. Telephone: 44-151-706-4175. Lead organization: National Cancer Research Institute. Age range: 18 and over.

SWS-SAKK-44/00, CECOG/PAN-1.3.001, EU-20142 Phase III Randomized Study of Gemcitabine With or Without Capecitabine in Patients With Advanced Pancreatic Cancer

Chairperson: Richard Herrmann, MD. Telephone: 41-61-265-5075. Lead organization: Swiss Institute for Applied Cancer Research. Age range: over 18.

CRUK-GEM-CAP, EU-20116 Phase III Randomized Study of Gemcitabine With or Without Capecitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Helen Hickey, BSc. Telephone: 00-44-151-706-4029. Lead organization: Cancer Research UK - Trials Office. Age range: over 18.

URCC-2200, NCI-5012, NCI-CCC-99-45, NCI-P02-0212 Phase III Randomized Study of Gemcitabine With or With-

out Dalteparin in Patients With Unresectable or Metastatic Pancreatic Cancer

Chairperson: Kishan J. Pandya, MD. Telephone: 585-275-5345. Lead organization: University of Rochester Cancer Center CCOP Research Base. Age range: 18 and over.

E-4201 Phase III Randomized Study of Gemcitabine With or Without Radiotherapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Chairperson: Patrick J. Loehrer, MD. Telephone: 317-278-7418; 1-888-600-4822. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

LORUS-LOR-VIR-P03-002 Phase III Randomized Study of Gemcitabine With or Without Virulizin Followed by Optional Second-Line Therapy With Virulizin or Placebo With or Without Fluorouracil in Patients With Chemotherapy-Naive Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Suzanne Cadden. Telephone: 416-798-1200. Lead organization: Lorus Therapeutics, Incorporated. Age range: 18 and over.

E-6201 Phase III Randomized Study of Prolonged Infusion Gemcitabine With Versus Without Oxaliplatin Versus Standard Infusion Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Elizabeth Poplin, MD. Telephone: 732-235-6777. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

WELLSTAT-401.00.001, PRONEURON-401.00.001, UAB-0105, UAB-F010524008 Phase III Randomized Study of Triacetyluridine and High-Dose Fluorouracil Versus Gemcitabine in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Lenny Smith, MS. Telephone: 240-631-2500 ext. 3238. Lead organization: Wellstat Therapeutics. Age range: 18 and over.

Phase II

MDA-2003-0530, NCI-6182 Phase II Study of CCI-779 in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Chairperson: Henry Qinghua Xiong, MD, PhD. Telephone: 713-792-2828; 800-392-1611. Lead organization: M. D. Anderson Cancer Center. Age range: 18 and over.

CALGB-80003 Phase II Study of Gemcitabine, Fluorouracil, and Radiotherapy in Patients With Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

Chairperson: Harvey Mamon, MD, PhD. Telephone: 617-732-7906. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

NHLBI-99-0064 Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients With Refractory Metastatic Solid Tumors

Chairperson: Richard Childs, MD. Telephone: 301-594-8013. Lead organization: National Heart, Lung, and Blood Institute. Age range: 10 to 80.

NCI NYU-9703, NCI-G98-1423 Phase I/II Study of Gemcitabine and Cisplatin Followed by Combined Chemoradiation and/or Surgical Resection in Patients With Locally Advanced Pancreatic Cancer

Chairperson: Howard S. Hochster, MD. Telephone: 212-652-1912. Lead organization: NYU School of Medicine's Kaplan Comprehensive Cancer Center. Age range: 18 and over.

FCCC-03003 Phase II Randomized Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma

Chairperson: Steven Cohen, MD. Telephone: 215-728-2450; 1-888-369-2571. Lead organization: Fox Chase Cancer Center. Age range: 18 and over.

E-E1200 Phase II Randomized Study of Gemcitabine and Radiotherapy Versus Gemcitabine, Fluorouracil, and Cisplatin Followed by Radiotherapy and Fluorouracil in Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Pancreas

Chairperson: John Parker Hoffman, MD. Telephone: 215-728-3518; 1-888-369-2571. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

UCLA-0207023, GENVEC-GV-001.004, NCI-G02-2131 Phase II Randomized Study of Intratumoral Adenovirus 5-Tumor Necrosis Factor Alpha (TNFerade) With Fluorouracil and Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Chairperson: Joel Randolph Hecht, MD. Telephone: 310-825-1469. Lead organization: Jonsson Comprehensive Cancer Center, UCLA. Age range: 18 to 80.

E-E8200 Phase II Randomized Study of Irinotecan and Docetaxel With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Pancreas

Chairperson: Barbara A. Burtness, MD. Telephone: 203-737-5064. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

VION-CLI-031 Phase II Study of 3-AP (Triapine) and Gemcitabine in Patients With Unresectable or Metastatic Pancreatic Cancer

Chairperson: Mario Sznol, MD. Telephone: 203-498-4210. Lead organization: Vion Pharmaceuticals, Inc. Age range: 18 and over.

ACOSOG-Z05031 Phase II Study of Adjuvant Chemoradiotherapy Comprising Fluorouracil, Cisplatin, and Interferon Alfa in Patients With Resected Pancreatic Adenocarcinoma

Chairperson: Vincent Picozzi, MD. Telephone: 206-223-6193. Lead organization: American College of Surgeons Oncology Group. Age range: 18 and over.

CMM-95079, CH/UMC-95079, NCI-V95-0760 Phase II Study of Interstitial Colloidal Phosphorus P32 Integrated Into the Treatment of Patients With Unresectable Pancreatic Cancer

Chairperson: Stanley Order, MD, ScD, FACR. Telephone: 516-222-5190. Lead organization: Center for Molecular Medicine. Age range: 18 and over.

PMH-PHL-015, NCI-5983 Phase II Study of Perifosine as Second-Line Therapy in Patients With Advanced Adenocarcinoma of the Pancreas

Chairperson: Malcolm J. Moore, MD. Telephone: 416-946-2263. Lead organization: Princess Margaret Hospital. Age range: 18 and over.

E1202 Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Chairperson: Robert de W. Marsh, MD. Telephone: 352-392-0058. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

MDA-ID-02040 Phase II Study of Postoperative Cisplatin, Interferon Alfa, Fluorouracil, and Concurrent Radiotherapy in Patients With Previously Resected Pancreatic Adenocarcinoma

Chairperson: Peter Pisters, MD. Telephone: 713-794-1572; 800-392-1611. Lead organization: University of Texas M.D. Anderson Cancer Center. Age range: 18 and over.

MSKCC-02049, NCI-5509 Phase II Study of UCN-01 and Fluorouracil in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

Chairperson: Gary K. Schwartz, MD. Telephone: 212-639-8324. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

Phase I

MSKCC-03031, NCI-5441 Phase I Study of Erlotinib, Gemcitabine, and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Cancer

Chairperson: Jeremy Kortmansky, MD. Telephone: 212-639-3344. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

MSKCC-02057, NCI-5764 Phase I Study of Flavopiridol in Combination With Radiotherapy Followed by Gemcitabine in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Chairperson: Gary K. Schwartz, MD. Telephone: 212-639-8324. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

MDA-DM-01553, NCI-5510 Phase I Study of UCN-01 and Gemcitabine in Patients With Unresectable or Metastatic Adenocarcinoma of the Pancreas

Chairperson: Linus Ho, MD. Telephone: 713-792-2828; 800-392-1611. Lead organization: University of Texas M.D. Anderson Cancer Center. Age range: 18 and over.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://www.cancer.gov/clinical_trials.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.